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Abstract 
Background: 
The rising financial burden of cancer on healthcare systems worldwide has led to increased demand 
for evidence-based research on which to base reimbursement decisions. Economic evaluations are 
an integral component of this necessary research. Ascertainment of reliable healthcare cost and 
quality of life estimates to inform such studies has historically been challenging, but recent advances 
in informatics in the UK provide new opportunities.  
Methods:  
The costs of hospital care for breast, colorectal and prostate cancer disease-free survivors were 
calculated over 15 months from initial diagnosis of cancer using routinely collected data within a UK 
National Health Service Hospital Trust. Costs were linked at patient level to patient-reported 
outcomes and registry-derived socio-demographic factors. Predictors of cost and the relationship 
between costs and patient-reported utility were examined.  
Results:   
The study population included 223 breast cancer patients, 145 colorectal and 104 prostate cancer 
patients. The 15 month cumulative healthcare costs were £12,595 (95% CI £11,517 - £13,722), 
£12,643 (£11,282 - £14,102) and £3,722 (£3,263 - £4,208) respectively. The majority of costs 
occurred within the first 6 months from diagnosis. Clinical stage was the most important predictor of 
costs for all cancer types. EQ-5D score was predictive of costs in colorectal cancer but not in breast 
or prostate cancer. 
Conclusion: 
It is now possible to evaluate healthcare cost using routine NHS datasets. Such methods can be 
utilised in future retrospective and prospective studies to efficiently collect economic data.  
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Introduction  
The cost of cancer is much discussed and of considerable relevance internationally given rising 
healthcare costs and financial constraint. The initial treatment period, rehabilitation and early 
follow-up after a new diagnosis of cancer incurs heavy resource demands on secondary care. 
Characterisation and prediction of these costs alongside other health outcomes is important for 
healthcare budget planning and service design aiming at improved efficiency. In particular economic 
evaluation is increasingly used to inform the allocation of scarce health resources, and many 
national reimbursement bodies (including the National Institute for Health and Care Excellence 
(NICE) in the United Kingdom (UK)) require the use of patient quality-adjusted life-years (QALYs) as 
an endpoint in economic evaluations (Drummond et al, 2005). Reliable analyses therefore require 
robust estimation of costs and patient quality-of-life (QoL).  There have been several attempts to 
describe the cost of cancer using insurance claims, registry data or manual case-note audit (Karnon 
et al, 2007; Mariotto et al, 2011; Tilson et al, 2012;(Brown et al, 1999; Yabroff et al, 2008; Krahn et 
al, 2010; de Oliveira et al, 2013). Methods applied in the UK, where detailed claims databases do not 
exist, either fail to capture local variation and full data granularity, or require a heavy data collection 
burden; accurate and easily reproducible estimates of the true cost of care therefore remain elusive. 
In the UK the National Health Service (NHS) provides universal publically funded healthcare which 
operates financially through a system of commissioning for services. Payments for defined episodes 
of care are calculated using a national tariff. In an attempt to improve the accuracy and national 
standardisation of the methods used to calculate this national tariff, Patient Level Information and 
Costing Systems (PLICS) are being developed (Francisci et al, 2013). Local pilots promoting national 
standardisation of methods using PLICS are on-going, under guidance from the Department of 
Health.  It is hoped that such systems, if fully implemented, will promote the ability to generate 
efficiency savings through improved service evaluation and planning (Blunt & Bardsley, 2012; Vogl, 
2012). Patient-level costing systems provide new opportunities for the calculation of the complete 
hospital-based cost of care. By accurately capturing patient level variation they offer an 
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improvement over current methods which rely on coded Human Resource Groups (HRGs) and 
assigned national standard tariffs.   
It is now accepted that assessments of patient quality of life should be embedded in routine care 
(Black, 2013). The NHS Patient Reported Outcome Measures (PROMS) initiative routinely collects 
quality of life data from a number of patient groups in England and is soon to be rolled out to cancer 
patients (Glaser et al, 2013). Identifying an efficient method to collect routine PROMs data linked to 
clinical and financial datasets is an essential prerequisite for robust future economic evaluation of 
cancer services. The electronic Patient-reported Outcomes from Cancer Survivors (ePOCS) project 
has designed and tested the technical and clinical feasibility of an electronic system for collecting 
patient-reported outcome data online and linking this with clinical cancer registry data (Ashley et al, 
2011b); through data linkage mechanisms it is now possible to also connect cost data with PROMS 
data using this new system. 
The primary aim of this paper is to describe the direct costs of hospital-based care for patients 
following a diagnosis of breast, colorectal or prostate cancer using routine NHS data. In particular, it 
aims to confirm the feasibility of data linkage between a new patient-level hospital finance system, 
electronic clinical records and electronically captured PROMs. The resulting composite dataset is 
then used to explore the extent to which clinical and socio-demographic factors predict NHS costs 
and quality of life over a 15 month period.  
 
Patients and Methods 
The costs of hospital-based care for breast, colorectal and prostate cancer disease-free survivors 
were calculated over 15 months from initial diagnosis of cancer using data collected during a 
feasibility study of the ePOCS system. The ePOCS system is a novel electronic system for collecting 
patient reported outcomes online and linking them with clinical cancer registry data. The feasibility 
study included collection of patient clinical, socio-demographic, cost and QoL data, which were used 
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in this analysis to explore total 15-month cumulative costs, cost predictors, and patient utility for 
disease-free survivors.  Comprehensive accounts of the design and development of the ePOCS 
system, and the protocol and results of the feasibility study have been published open-access 
(Ashley et al, 2011a, 2013). In brief, English-literate adult patients within six months of a diagnosis of 
early breast, colorectal or prostate cancer being treated with curative intent were recruited from 
Leeds Teaching Hospitals NHS Trust (LTHT) and Calderdale & Huddersfield NHS Foundation Trust 
(CHFT). Eligible patients were identified during routine multidisciplinary meetings and/or through 
consultation of medical notes by NHS research nurses and/or oncology clinicians. The recruitment 
period was November 2010 to September 2011. Participants were asked to complete PROMs online 
using the ePOCS system at three time points: T1, within 6 months of diagnosis, T2 at 9 months post-
diagnosis and T3 at 15 months post-diagnosis. dŚĞWZKDƐĚĂƚĂǁĞƌĞ ůŝŶŬĞĚǁŝƚŚƉĂƚŝĞŶƚƐ ?clinical 
registry data and stored in the National Cancer Data Repository.  
The cost analysis included all hospital-based costs incurred over the 15-month follow-up period in 
the LTHT population. Day zero was defined as the date of diagnosis, recorded from the medical 
notes by the research nurse at the time of patient consent to the ePOCS study. Patients were 
diagnosed between May 2010 and September 2011. Costs were adjusted to the common base year 
of 2011-12 using the Personal Social Services Research Unit (PSSRU) Hospital and community health 
services (HCHS) pay and prices index. Confidence intervals were calculated for all analyses using the 
bootstrap method. Analysis of costs was conducted using regression analysis performed on log-
costs, which were approximately normally distributed and did not contain zeros, using the ordinary 
least squares method. The explanatory variables age, gender, oncological stage, Index of Multiple 
Deprivation (IMD) and baseline EQ-5D (T1) were established a priori; all of which were included in 
univariate and multivariate analyses. Complete case analysis was used for individual EQ-5D 
regressions. The complete 15 months of follow-up was available for all patients. Patients who died 
or suffered a cancer relapse (i.e. ceased to be disease free) during this period were identified from 
the clinical record and excluded on the grounds that this study reports the outcomes specific to 
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disease-free survivors.  All analysis was carried out using the R statistical software package version 
3.0.0 (R et al, 2009).   
 
Data capture and linkage 
The cost analysis was based on finance data from patients recruited at LTHT only, due to the fact 
that PLICS data was unavailable for patients recruited at CHFT.  PROMs data was available from both 
LTHT and CHFT; the analysis of patient utility therefore utilized data from patients recruited at both 
LTHT and CHFT.  
1. Clinical data:  The LTHT Oncology department uses a computer-based system called Patient 
Pathway Manager (PPM) which links the various clinical data systems within the LTHT and maintains 
an electronic patient record. PPM includes information on demographics, pathology, radiology, 
surgery, chemotherapy and radiotherapy. The ePOCS study information was also held within PPM 
allowing internal linkage of ePOCS study ID, NHS number and other identifiers (Newsham et al, 
2011). 
2. Finance data: Patient records within LTHT from PPM were individually linked to costs held within 
the local pilot database of the national PLICS scheme using ĞĂĐŚƉĂƚŝĞŶƚ ?Ɛ NHS number. This provides 
a cost for hospital-based accident and emergency department visits, outpatient attendances and 
inpatient stays.  Individual care episodes are coded using the national HRG version 4 codes. HRG 
costing uses a mixture of (a) top down costing  ? where cost pools (used to collect indirect and 
overhead costs) are allocated to HRGs using the total cost of that cost pool weighted for each HRG 
based upon the best available data and, (b) bottom up costing  ? which builds up the costs of an HRG 
from known local expenditure (e.g. prosthetics in hip replacement) HRGs (Department of Health 
Payment by Results team, 2012). HRG codes include the average cost of intravenous and oral 
chemotherapies.   
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3. Socioeconomic data: A marker of socio-economic status was ascertained by calculating IMD scores 
and quintiles from ƉĂƚŝĞŶƚƐ ?postcodes recorded in PPM; the first quintile contains patients living in 
the most deprived areas and the fifth quintile contains patients living in the least deprived areas 
(Department for Communities and Local Government, 2011).   
4. Patient Reported Outcome data: Over the three time-points participants treated at LTHT and CHFT 
were asked to complete a range of PROMs, which assessed patients ?  psychosocial and socio-
demographic status (e.g. education level, employment status etc.), quality-of-life and disease 
specific (breast, colorectal and prostate cancer) variables. The analysis presented here utilizes 
PROMs data on patient health status as measured by the EQ-5D version 2 questionnaire, collected at 
T1, T2 and T3. Complete case analysis was used to maximise reproducibility in future studies that 
build on this pilot.  
The EQ-5D questionnaire measures health status across five domains:  mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression. Respondents specify whether they have no 
problems, some problems or severe problems within each domain, on the day of response. Utility 
scores were derived from the EQ-5D responses using preferences for health states elicited from the 
UK general public  (The EuroQol Group, 1990; Gudex et al, 1995). A maximum utility score of 1 
represents the state of being in full health; zero represents the state of being dead. The EQ-5D has 
been used widely in cancer studies (Pickard et al, 2007b), and is regarded as the gold-standard 
measure of quality of life in the UK as specified by NICE for the calculation of QALYs. We compared 
paƚŝĞŶƚƐ ?ƵƚŝůŝƚǇƐĐŽƌĞƐǁŝƚŚĂŐĞ- and sex-matched population norms obtained from a survey of the 
UK population (Kind et al, 1998).   
Ethical approval was given for the ePOCS study from the NHS Leeds (East) Research Ethics 
Committee (10/H1306/65). Patients provided written informed consent. 
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Results 
Patient characteristics 
In total there were 636 patients consented into the ePOCS study across LTHT and CHFT. The mean 
patient age was 63 (range 23-92). Full details of the patient demographics and baseline 
characteristics are available in the open-access ePOCS study feasibility report (Ashley et al, 2013).  
There were 297 patients with breast cancer, 192 with colorectal cancer and 147 with prostate 
cancer. Patients not classified as survivors within the 15 month study period were excluded; these 
included patients who developed new primary cancers, recurrent cancer or had died. The final study 
population meeting eligibility consisted of 223 patients with breast cancer, 145 with colorectal 
cancer and 104 with prostate cancer from LTHT, and 68 with breast cancer, 19 with colorectal cancer 
and 36 with prostate cancer from CHFT (see Figure 1). Baseline patient characteristics are described 
in Table 1. Overall, the mean age was 56 (median 55, standard deviation (sd) 10.7) for the breast 
patients, 63 (median 63, sd 9.1) for the colorectal patients and 65 (median 65, sd 6.6) for the 
prostate patients. For the cost analysis, complete data was available. For the analysis of patient 
utility, over 92% of EQ-5D questionnaires were returned at 6 months across all cancers, however this 
dropped to around 70% at 15 months for breast and colorectal cancer, and 82% for prostate cancer. 
Using the NHS number alone, linkage between the LTHT PLICS finance database, the electronic 
clinical record and the ePOCS study database was 100%.  
Hospital costs 
Costs for breast and colorectal cancer were similar and considerably higher than those for prostate 
cancer. For breast cancer patients the mean cumulative hospital costs at 6, 9 and 15 months (with 
95% CIs) were £9,557 (£8,893 - £10,220), £11,175 (£10,339 - £12,059) and £12,595 (£11,517 - 
£13,722), respectively. For colorectal cancer the corresponding figures were £10,038 (£9,015 - 
£11,131), £11,809 (£10,551 - £13,109) and £12,643 (£11,282 - £14,102) and for prostate cancer 
£2,807 (£2,398 - £3,233), £3,407 (£2,977 - £3,846) and £3,722 (£3,263 - £4,208). In each cancer at 
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least 75% of the total costs at month 15 were incurred by month 6. Figure 2 illustrates the decline in 
costs over time in all cancers with small rises around the 6 and 12 month follow-up visits.  
The mean costs by subgroup suggest that the below 65 age group incurred greater costs than the 65 
and over group and that costs increase with disease stage (Figure 3). Tables 2 and 3 include the 
univariate and multivariate analyses, respectively, predicting 15 month costs. In each case disease 
stage appears to be the strongest predictor of costs.  
Utility 
Figure 4 depicts the mean EQ-5D score at 6, 9 and 15 months for each of the three cancer types. The 
mean EQ-5D scores for patients with each cancer type increased over time, generally plateauing 
after one year from diagnosis. Breast cancer patients had the worst utility and the smallest 
improvements over time, which may reflect more aggressive adjuvant treatment over a longer time 
period compared to the two other cancer types. Older breast cancer patients also had higher utility 
than younger patients across the three time-points, possibly for the same reasons. There was a 
trend suggesting that those living in areas of higher deprivation (lower IMD groups) had lower 
quality of life scores compared with those living in more affluent areas. However, the multivariate 
regression of the EQ-5D scores (results in supplementary material) found no significant predictors of 
utility at any time-point for any cancer.  
A full breakdown of the cumulative costs and EQ-5D score at 6, 9 and 15 months from diagnosis for 
each tumour type, clinical subgroups and treatment modalities is provided in the supplemental 
appendix. EQ-5D score at T3 demonstrated only minimal correlation with cumulative costs with a 
WĞĂƌƐŽŶ ?ƐĐŽƌƌĞůĂƚŝŽŶĐŽĞĨĨŝĐŝĞŶƚ of -0.06 for breast cancer, -0.20 for colorectal cancer and -0.10 for 
prostate cancer. A low EQ-5D score at T1 was associated with higher 15 month cumulative costs but 
this only reached statistical significance in univariate and multivariate analysis for colorectal cancer 
(Tables 2 and 3). 
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Comparisons with population norms indicated that breast cancer patients had significantly lower EQ-
5D score than an age- and sex-matched reference population. Conversely, prostate cancer patients 
were found to have significantly higher scores than the reference population.  No significant 
difference was found for colorectal cancer patients (Table 4). 
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Discussion 
Traditionally cost and cost-effectiveness analyses in the UK have employed techniques such as hand 
searching patient records, asking patients to complete resource use questionnaires, or use of a 
combination of different methods from diverse sources in order to collect cost and outcomes data 
(Karnon et al, 2007). For studies with large sample sizes and longitudinal analyses these methods are 
particularly time consuming and have the potential for bias due to discrepancies in records both 
within and between facilities. More recently, use of Hospital Episode Statistics (HES) has gained 
popularity within cost analysis (Gaughan et al, 2012). HES provides electronic access to over 125 
million outpatient, inpatient and accident and emergency attendances in England and is increasingly 
used for economic analysis negating to some extent the need to manually collect details of resource 
use from patient records. However, there has been debate over the completeness of HES data and 
constraints in the range of activity covered (Spencer & Davies, 2012). In addition, manual hand 
searching, patient questionnaires and HES all require unit costs to be assigned to the resource use, 
ĚĞƐĐƌŝďĞĚĂƐĂ ‘ƚŽƉ-ĚŽǁŶ ?ĐŽƐƚŝŶŐĂƉƉƌŽĂĐŚ ?hƐĞŽĨW>/^ĚĂƚĂĨŽƌƚŚŝƐƚǇƉĞŽf economic evaluation is 
ďĂƐĞĚ ŽŶ ůŽĐĂů  ‘ďŽƚƚŽŵ-ƵƉ ? ĐŽƐƚŝŶŐ ƚĞĐŚŶŝƋƵĞƐ ? ǁŚĞƌĞ ƚŚĞ ĐŽƐƚƐ ŽĨ ƐƉĞĐŝĨŝĐ ƉƌŽĐĞĚƵƌĞƐ Žƌ ĐĂƌĞ
episodes reflect the real local expenditure required to provide them. Analysis using a PLICS database 
is less onerous, time-consuming and costly than hand searching patient records and is unlikely to 
suffer potential difficulties associated with recall bias. Local unit costs are included in each PLICS 
database and the granularity and range of the data is likely to have fewer constraints than HES data.  
In the UK, the patient level information and costing system (PLICS) initiative led to coordinated local 
piloting in 2009 with the primary objective of providing NHS organizations a better understanding of 
their drivers of costs (Department of Health, 2011). The intention of this system is to provide an 
electronic means by which to measure the resources consumed by individual patients. Such data 
may then be used to understand variations in services. When linked with clinical care and outcomes 
data, improved clinical ownership of resource decisions and evidence-based analysis also becomes 
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possible (Francisci et al, 2013). PLICS is not compulsory across the NHS, and by 2010 few Trusts had 
implemented the system. Early indications suggest it is a useful tool to provide accurate data on 
spending against income (Blunt & Bardsley, 2012). This is the first study to assign costs to the clinical 
cancer care pathway using linkage between PLICS and clinical datasets. It also has the added 
advantage of linked quality-of-life data, providing proof of concept for a comprehensive routine 
electronic dataset for technology evaluation.  
This study adds substantially to the current limited literature on the costs of hospital-based cancer 
care using robust, efficient and reproducible methods. To our knowledge this is the first UK study to 
report costs in this manner for the initial year after diagnosis and certainly the largest study of its 
kind to date. Two previous studies have looked at the costs of recurrent breast cancer with 
estimates between £12,000 and £25,000 for the first year after diagnosis of a recurrence in patients 
with a previously treated breast cancer (Karnon et al, 2007; Thomas et al, 2009). Both studies use a 
top-down HRG based ĐŽƐƚŝŶŐŵĞƚŚŽĚ ?dŚŝƐ ĐŽŵƉĂƌĞƐǁŝƚŚŽƵƌƐƚƵĚǇ ?ƐŚĞĂĚůŝŶĞ  ? ?ŵŽŶƚŚĐŽƐƚ ĨŽƌ
new breast cancer patients of £12,595.   
The cost analysis was based on data from one of the biggest NHS trusts in the country, which offers a 
range of both general and specialist hospital services. The results are therefore likely to be broadly 
generalizable across the UK population to similar sized populations. Care should be taken when 
attempting to apply these cost results in a non-UK context, as the specific configuration of individual 
national health care service provision- which has a major impact on how and where costs are likely 
to be incurred- can vary significantly from country to country. An advantage of this study is that it 
enables adjustment of both costs and EQ-5D scores based on clinical and demographic factors, 
allowing greater representations of local populations with well-defined characteristics.    
Overall this analysis found that baseline staging and related clinical characteristics were the 
strongest predictors of hospital costs. Within breast cancer significant predictors were lymph node 
status, grade and molecular markers (HER2 and hormone status); for colorectal cancer, Dukes 
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classification and for prostate cancer the Gleason score. Socio-demographic variables were of less 
importance as predictors of cost. There was no clear association between treatment costs and Index 
of Multiple Deprivation (IMD). This is surprising given that health inequalities have previously been 
seen to be associated with poorer health and health outcomes and higher treatment costs (Marmot 
et al, 2010). It may, however, be explained by a limitation of the study, whereby all people involved 
in ePOCS had to be able to access the internet. Inevitably this meant that the trend common in 
routine clinical trials, whereby fewer older people living in areas of greater deprivation enroll in 
studies, was exacerbated in this study (Sateren, 2002; Murthy et al, 2004). There was a significant 
difference in IMD quintile between those who consented and refused study participation (P < ·001) 
and IMD quintile was the only significant predictor of retention in a regression analyses. In addition, 
our analysis showed no correlation between IMD and staging in contrast to evidence to suggest IMD 
predicts clinical outcome (Downing et al, 2007).  
Our univariate analyses showed significant differences in costs by age, but these differences were no 
longer significant (at the 99% level) in the multivariate analyses. Despite the lack of statistical 
significance a clear trend exists suggesting that older patients (65 and over) are associated with 
lower costs than younger patients. In the case of breast cancer this may be explained by younger 
patients presenting with higher disease stage, as well as more aggressive treatment of younger 
patients. In colorectal and prostate cancer it is unclear why this might be and whether this is related 
to demand-side (patients actively consuming more health care resources  ? e.g. contacting the doctor 
more frequently) or supply-side factors (healthcare professionals providing more health care 
resources  ? e.g. conducting more tests or suggesting more frequent visits). The absence of 
information about co-morbidity is a clear limitation of this study as it is likely that co-morbidity 
contributes to differences in costs between age groups. 
The multivariate regression of the EQ-5D scores found no significant predictors of quality of life at 
any time-point for the three cancer types. The lack of significance may be a function of the relatively 
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limited sample size, particularly for the EQ-5D analysis due to the limitation of missing data. The 
descriptive analysis on the EQ-5D by subgroup did provide some interesting results. In line with 
expectations, the quality of life for patients with the three cancer types increased over time from 
diagnosis and radical treatment. Breast cancer patients appear to have the worst quality of life and 
the smallest improvements in quality of life over time. This may be related to the continuing 
psychological impact of mastectomy, especially in a sample that is young relative to the other 
cancer-type patients. There was the interesting finding that younger women with breast cancer have 
worse quality of life than older women. This confirms the findings in this regard of a number of other 
studies (Calman, 1984; Hopwood et al, 2007). In contrast, conventional wisdom in non-breast cancer 
patients based on many analyses of EQ-5D data including population norms and Health Survey for 
England data has concluded that quality of life declines with age (Maheswaran et al, 2013). Indeed 
we see in the prostate and colorectal cancer groups that older patients have lower EQ-5D scores, 
even when stratified by gender. It is not clear why this quality of life reversal by age group exists in 
breast cancer. It is possible that the impact of cancer is greater in younger patients due to greater 
psychological distress, or appears greater due to questionnaire responses being reference based (to 
the health of similarly aged-peers) or expectation-based. A number of mean between-group 
differences in quality of life appeared non-trivial and in the order of magnitude of a difference that 
could be considered important (between 0.06-0.12) (Pickard et al, 2007a). These include the 
differences between breast and prostate cancer patients, differences between age groups in breast 
cancer and between the highest and lowest IMD groups. The quality of life of the three sets of 
cancer patients appears roughly in line with population norms with the exception that younger 
breast cancer patients experience a decrement and the patients with prostate cancer have 
consistently higher scores. The colorectal cancer patients are almost the same as the population 
norms. The recruitment and retention within the ePOCS study is biased due to both deprivation and 
age, in common in many trials and exaggerated in ePOCS due to the reliance on information 
technology. This may explain higher than expected quality of life. The association seen between T1 
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EQ-5D scores and cumulative costs is intuitive given that more intensive treatments such as 
chemotherapy and radiotherapy may cost more and increase morbidity.  
>d,d ?Ɛ W>/^ ƐǇƐƚĞŵ ŝƐ ĐŽŶƐƚƌƵĐƚĞĚ ƵƐŝŶŐ ŶĂƚŝŽŶĂůůǇ ƌĞĐŽŐŶŝƐĞĚ ĐŽƐƚŝŶŐ ƉƌŝŶĐŝƉůĞƐ ĂŶĚ ŵĞƚŚŽĚƐ ?
supplemented where appropriate by locally determined rules and arrangements relevant and 
appropriate to PLICS, and having been determined in consultation with divisional clinical, operational 
and finance representatives initially and since by regular review. Effort to date has predominantly 
been focussed on refining the inputs to the system and, at the time of writing, there has been no 
systematic, widespread review of PLICS outputs across LTHT amongst operational and clinical staff. 
This is something which, following a recent Trust restructuring and the creation of Clinical Service 
Units, the Trust is now embarking upon using 2012-13 PLICS data. Until this systematic validation 
takes place LTHT PLICS data must be treated with caution. Additionally the Trust is conscious of a 
number of areas of NHS service provision in which the linking of costs to patients is still not possible, 
such as catering services and housekeeping; this may impact differentially on services evaluated.  
This analysis considered hospital post-diagnosis costs over a 15-month follow-up period. A full 
analysis of costs requires additional consideration of both primary and community care costs, as well 
as costs incurred pre-diagnosis and in the longer term. We will be attempting to quantify these 
additional costs in future planned analyses. 
This paper has described an analysis based on data generated by employing a novel method of 
capturing patient-reported outcome data and linking that with clinical and cost data from hospitals. 
The feasibility and utility of such data linkage now being evident, further efforts to routinely collect 
and link such data is encouraged. The results described here will be of use to health economic 
modellers requiring cost and utility estimates to populate decision-analytical models. The results 
have implications for health economic analysis and modelling in cancer. Firstly, costs decline rapidly 
after the initial treatment phase but have small peaks around the routine visit time-points; thus 
analysts should have differential cost estimates in year 1 versus subsequent years. Unsurprisingly, 
Page 17 of 20 
costs differ by disease stage but also more unexpectedly by age with younger patients being 
associated with greater costs. The latter point is worthy of further investigation. The quality of life of 
patients recovering from cancer does not appear substantively different from age-specific 
population norms with the exception of younger women with breast cancer, although this finding 
may be a result of potential patient selection bias as previously discussed. Future economic analyses 
of breast cancer interventions should bear in mind the quality of life decrement that accompanies 
breast cancer in younger groups in addition to the time-varying and subgroup-varying nature of 
secondary healthcare costs.  
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